News

GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise

As per terms of the deal, Catalent will involve in the development of a powder-in-capsule formulation for Ennaid’s ENU200 programme. Ennaid’s ENU200 is a patent-pending and repurposed oral

The application for TUKYSA approval was reviewed by Swissmedic as part of Project Orbis, an initiative of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence

In the late-stage trial called IKEMA, Sarclisa, when added to carfilzomib and dexamethasone, met the primary endpoint by delivering significantly prolonged progression-free survival compared to standard of care

“We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” said Michael Goldstein, MD, MBA, Chief Medical Officer. “We believe that the intracanalicular

Earlier this month, the FDA has completed its review of Moderna’s investigational new drug (IND) application for mRNA-1273 to conduct Phase 2 study, which is expected to be

Favipiravir is approved in Japan as the anti-influenza drug Avigan. With FFTC providing support through donated drug product, the phase 2 study will be conducted at long-term care

In this regard, the Texas-based Acer Therapeutics has signed a research collaboration agreement with NCATS, which is one of the National Institutes of Health (NIH) in the US.

“RMAT designation is another important regulatory milestone for CTX001 and underscores the transformative potential of a CRISPR-based therapy for patients with severe hemoglobinopathies,” said Samarth Kulkarni, Ph.D., Chief